Beyond Air Faces Nasdaq Compliance Challenges Amid Losses

Beyond Air Inc. (NASDAQ: XAIR) Overview

Beyond Air Inc., founded in 2011 and formerly known as AIT Therapeutics, is a clinical-stage medical device and biopharmaceutical company headquartered in Garden City, New York. The company develops and commercializes nitric oxide (NO) generation and delivery systems under the LungFit® family of products. Using patented Ionizer™ and Plasma Pulse Technology™, LungFit devices produce inhaled NO from ambient air, eliminating the need for high-pressure cylinders.

Corporate Structure and Experience

Beyond Air operates as a small to mid-sized enterprise with between 11 and 50 employees. Its leadership team includes Steve Lisi (Chief Executive Officer and Chairman of the Board) and key executives with experience in respiratory therapy and medical device innovation. The board of directors includes Erick Lucera, Yoori Lee, Bill Forbes, PharmD, Robert F. Carey, and Robert Goodman, PharmD.

Recent Developments and News

• SEC Form 8-K Filing (June 18, 2025): Beyond Air announced updates under Items 2.02 (Results of Operations and Financial Condition), 5.02 (Departure of Directors or Certain Officers), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). Details included leadership appointments and operational milestones.
• U.S. Patent Issuance (May 2025): Patent No. 12,274,830 was granted for a method of delivering gaseous nitric oxide to treat non-tuberculous mycobacteria (NTM) lung infections.
• Nasdaq Compliance Extension (June 2025): Nasdaq granted a 180-day extension—expiring August 4, 2025—for Beyond Air to regain compliance with the minimum bid price requirement of $1.00 per share. The company may consider a reverse stock split to meet listing standards.
• Definitive Proxy Statement (May 5, 2025): Shareholders will vote on June 20, 2025, on a proposed reverse stock split ranging from 1-for-10 to 1-for-50 and an adjournment proposal to secure sufficient votes.
• Schedule 13G/A Amendment (May 15, 2025): Balyasny Asset Management and affiliates reported beneficial ownership of 12,290,913 shares, representing 9.99% of outstanding common stock, with sole voting and dispositive power.
• Trading Activity (June 19, 2025): Shares closed at $0.2023, down 29.02% on volume of 10,867,455.

Financial and Strategic Analysis

As of June 19, 2025, Beyond Air’s common shares trade at $0.2023, valuing the company at an intraday market cap of approximately $17.5 million. Key financial metrics (trailing twelve months):

• Revenue: $3.71 million
• Net Income: –$46.62 million
• Diluted EPS: –0.69
• Total Cash (most recent quarter): $6.92 million
• Total Debt/Equity (most recent quarter): 64.13%
• Price/Sales: 3.70
• Price/Book: 1.29

The company's cash balance highlights the importance of strategic financing or potential reverse split to maintain compliance with Nasdaq listing requirements. Beyond Air projects FY 2026 revenue of $12 million to $16 million, stemming from ongoing clinical trials in viral pneumonia, NTM lung infections, and pulmonary arterial hypertension.

Market Position and Industry Context

Beyond Air operates in the medical equipment manufacturing sector, specializing in inhaled nitric oxide therapy. LungFit devices differentiate through on-demand NO generation from room air and a compact form factor. The company’s technology addresses logistical challenges in respiratory care. Clinical validation and regulatory approvals remain critical for broader market access. Institutional investors such as Alyeska Investment Group and Balyasny Asset Management hold substantial stakes in the company.

tl;dr

Beyond Air shares have decreased to $0.2023 as of June 19, 2025, following Nasdaq's grant of a 180-day extension to meet the $1.00 minimum bid price requirement. A U.S. patent for NTM lung infection treatment supports the LungFit portfolio, while a shareholder vote on a reverse stock split aims to preserve listing compliance. TTM revenue is $3.71 million against a net loss of $46.62 million, and the company holds $6.92 million in cash. Future performance may depend on clinical trial outcomes, regulatory approvals, and financing actions to support FY 2026 revenue guidance of $12 million to $16 million.